Bliss GVS Pharma Limited has informed the Exchange that the Board of Directors at its meeting held today i.e. Monday, May 12, 2025 has approved the issuance and allotment of Sweat Equity Shares to the members of the Promoter and Promoter Group of the Company.
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.4 pts less than Nifty Microcap 250 and 1.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bliss GVS Pharma's Board, at its meeting on May 12, 2025, approved the issuance and allotment of up to 12,10,000 Sweat Equity Shares of Re. 1 face value for non-cash consideration. Of these, 8,50,000 shares will go to Mr. Gagan Harsh Sharma (Managing Director) and 3,60,000 to Mr. Vishal Vijay Rao (Vice President), both from the Promoter and Promoter Group. The shares are being issued under SEBI's Sweat Equity Regulations to recognize their value additions and ongoing contributions to the company. The allotment is subject to shareholder and other regulatory approvals. No cash is being raised by the company through this issuance.
This will lead to a slight dilution of existing shareholders' equity (up to 12.10 lakh new shares issued without cash inflow), though it aligns promoter interests with company performance. Shareholders may view this neutrally as the shares are awarded for past contributions rather than as a fresh capital raise.